VISTA+/CD8+ status correlates with favorable prognosis in Epithelial ovarian cancer

Immunotherapy by blocking immune checkpoint regulators has emerged as a new targeted therapy for some cancers. Among them V-domain Ig suppressor of Tcell activation (VISTA) which is identified as a novel checkpoint regulator in ovarian cancer. This study aimed to investigate the VISTA role in Epithe...

Full description

Bibliographic Details
Main Authors: Aida Jlassi, Maroua Manai, Maram Morjen, Ghada Sahraoui, Monia Elasmi Allal, Ines ELBini-Dhouib, Lamia Naija, Lamia Charfi, Rim Rejaibi, Melika Ben Ahmed, Naziha Marrakchi, Najet Srairi-Abid, Amel Mezlini, Mohamed Manai, Karima Mrad, Raoudha Doghri
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035885/?tool=EBI
_version_ 1797860179694321664
author Aida Jlassi
Maroua Manai
Maram Morjen
Ghada Sahraoui
Monia Elasmi Allal
Ines ELBini-Dhouib
Lamia Naija
Lamia Charfi
Rim Rejaibi
Melika Ben Ahmed
Naziha Marrakchi
Najet Srairi-Abid
Amel Mezlini
Mohamed Manai
Karima Mrad
Raoudha Doghri
author_facet Aida Jlassi
Maroua Manai
Maram Morjen
Ghada Sahraoui
Monia Elasmi Allal
Ines ELBini-Dhouib
Lamia Naija
Lamia Charfi
Rim Rejaibi
Melika Ben Ahmed
Naziha Marrakchi
Najet Srairi-Abid
Amel Mezlini
Mohamed Manai
Karima Mrad
Raoudha Doghri
author_sort Aida Jlassi
collection DOAJ
description Immunotherapy by blocking immune checkpoint regulators has emerged as a new targeted therapy for some cancers. Among them V-domain Ig suppressor of Tcell activation (VISTA) which is identified as a novel checkpoint regulator in ovarian cancer. This study aimed to investigate the VISTA role in Epithelial ovarian cancer (EOC), and its relationship with tumor-infiltrating lymphocytes (TILs) markers and its prognostic value. The expression of VISTA, CD3, CD8, CD4, FOXP3, and CD56 was assessed in 168 EOC tissue microarrays (TMA) by immunohistochemistry (IHC). In addition, associations between VISTA, TILs, clinicopathological variables, and overall survival (OS) were analyzed. VISTA expression in IGRov1 cells, as well as in PBMC of EOC patient, was evaluated by western blot. VISTA expression was detected in 64,28% of tissues, among which 42.3% were positive for tumor cells (TCs), and 47,9% were positive for immune cells (ICs). In univariate analysis, VISTA expression was significantly associated with a high density of TILs:CD3+ (p = 0,001), CD4+ (p = 0,002) and CD8+ (p≤0,001), in ICs but not in TCs. In terms of OS, multivariate analysis showed a significant association between the high density of CD8+ TILs and VISTA positive staining in ICs (p = 0,044), but not in TCs (p = 0,108). Kaplan-Meier curves demonstrated no correlation between VISTA expression and prolonged OS in both ICs (p = 0,841) and TCs (p = 0,090). Classification of EOC tumor microenvironment based on VISTA and CD8+TILs expression, demonstrated four immune subtypes: VISTA+/CD8+, VISTA+/CD8-, VISTA-/CD8+ and VISTA-/CD8-. The dual positive VISTA+/CD8+ subtype was significantly associated with prolonged OS in both TCs and ICs (p = 0,012 and p≤0,01, respectively), whereas patients with VISTA+/CD8- had the worst OS. Our results showed that VISTA is highly expressed in the IGRov1 cell line and LT-CD8 from a patient with EOC. Our results highlighted the association of VISTA expression and CD8+ TILs in EOC, with prolonged OS in patients with VISTA+/CD8+ and proposed VISTA as a potential immunotherapeutic target in EOC.
first_indexed 2024-04-09T21:41:38Z
format Article
id doaj.art-c75f223ac7b34379b321b13bb100881e
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-04-09T21:41:38Z
publishDate 2023-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-c75f223ac7b34379b321b13bb100881e2023-03-26T05:32:02ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-01183VISTA+/CD8+ status correlates with favorable prognosis in Epithelial ovarian cancerAida JlassiMaroua ManaiMaram MorjenGhada SahraouiMonia Elasmi AllalInes ELBini-DhouibLamia NaijaLamia CharfiRim RejaibiMelika Ben AhmedNaziha MarrakchiNajet Srairi-AbidAmel MezliniMohamed ManaiKarima MradRaoudha DoghriImmunotherapy by blocking immune checkpoint regulators has emerged as a new targeted therapy for some cancers. Among them V-domain Ig suppressor of Tcell activation (VISTA) which is identified as a novel checkpoint regulator in ovarian cancer. This study aimed to investigate the VISTA role in Epithelial ovarian cancer (EOC), and its relationship with tumor-infiltrating lymphocytes (TILs) markers and its prognostic value. The expression of VISTA, CD3, CD8, CD4, FOXP3, and CD56 was assessed in 168 EOC tissue microarrays (TMA) by immunohistochemistry (IHC). In addition, associations between VISTA, TILs, clinicopathological variables, and overall survival (OS) were analyzed. VISTA expression in IGRov1 cells, as well as in PBMC of EOC patient, was evaluated by western blot. VISTA expression was detected in 64,28% of tissues, among which 42.3% were positive for tumor cells (TCs), and 47,9% were positive for immune cells (ICs). In univariate analysis, VISTA expression was significantly associated with a high density of TILs:CD3+ (p = 0,001), CD4+ (p = 0,002) and CD8+ (p≤0,001), in ICs but not in TCs. In terms of OS, multivariate analysis showed a significant association between the high density of CD8+ TILs and VISTA positive staining in ICs (p = 0,044), but not in TCs (p = 0,108). Kaplan-Meier curves demonstrated no correlation between VISTA expression and prolonged OS in both ICs (p = 0,841) and TCs (p = 0,090). Classification of EOC tumor microenvironment based on VISTA and CD8+TILs expression, demonstrated four immune subtypes: VISTA+/CD8+, VISTA+/CD8-, VISTA-/CD8+ and VISTA-/CD8-. The dual positive VISTA+/CD8+ subtype was significantly associated with prolonged OS in both TCs and ICs (p = 0,012 and p≤0,01, respectively), whereas patients with VISTA+/CD8- had the worst OS. Our results showed that VISTA is highly expressed in the IGRov1 cell line and LT-CD8 from a patient with EOC. Our results highlighted the association of VISTA expression and CD8+ TILs in EOC, with prolonged OS in patients with VISTA+/CD8+ and proposed VISTA as a potential immunotherapeutic target in EOC.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035885/?tool=EBI
spellingShingle Aida Jlassi
Maroua Manai
Maram Morjen
Ghada Sahraoui
Monia Elasmi Allal
Ines ELBini-Dhouib
Lamia Naija
Lamia Charfi
Rim Rejaibi
Melika Ben Ahmed
Naziha Marrakchi
Najet Srairi-Abid
Amel Mezlini
Mohamed Manai
Karima Mrad
Raoudha Doghri
VISTA+/CD8+ status correlates with favorable prognosis in Epithelial ovarian cancer
PLoS ONE
title VISTA+/CD8+ status correlates with favorable prognosis in Epithelial ovarian cancer
title_full VISTA+/CD8+ status correlates with favorable prognosis in Epithelial ovarian cancer
title_fullStr VISTA+/CD8+ status correlates with favorable prognosis in Epithelial ovarian cancer
title_full_unstemmed VISTA+/CD8+ status correlates with favorable prognosis in Epithelial ovarian cancer
title_short VISTA+/CD8+ status correlates with favorable prognosis in Epithelial ovarian cancer
title_sort vista cd8 status correlates with favorable prognosis in epithelial ovarian cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035885/?tool=EBI
work_keys_str_mv AT aidajlassi vistacd8statuscorrelateswithfavorableprognosisinepithelialovariancancer
AT marouamanai vistacd8statuscorrelateswithfavorableprognosisinepithelialovariancancer
AT marammorjen vistacd8statuscorrelateswithfavorableprognosisinepithelialovariancancer
AT ghadasahraoui vistacd8statuscorrelateswithfavorableprognosisinepithelialovariancancer
AT moniaelasmiallal vistacd8statuscorrelateswithfavorableprognosisinepithelialovariancancer
AT ineselbinidhouib vistacd8statuscorrelateswithfavorableprognosisinepithelialovariancancer
AT lamianaija vistacd8statuscorrelateswithfavorableprognosisinepithelialovariancancer
AT lamiacharfi vistacd8statuscorrelateswithfavorableprognosisinepithelialovariancancer
AT rimrejaibi vistacd8statuscorrelateswithfavorableprognosisinepithelialovariancancer
AT melikabenahmed vistacd8statuscorrelateswithfavorableprognosisinepithelialovariancancer
AT nazihamarrakchi vistacd8statuscorrelateswithfavorableprognosisinepithelialovariancancer
AT najetsrairiabid vistacd8statuscorrelateswithfavorableprognosisinepithelialovariancancer
AT amelmezlini vistacd8statuscorrelateswithfavorableprognosisinepithelialovariancancer
AT mohamedmanai vistacd8statuscorrelateswithfavorableprognosisinepithelialovariancancer
AT karimamrad vistacd8statuscorrelateswithfavorableprognosisinepithelialovariancancer
AT raoudhadoghri vistacd8statuscorrelateswithfavorableprognosisinepithelialovariancancer